Partnerships keep us at the forefront of new drug development
IBsolvMIR has a strong preclinical foundation demonstrating outstanding efficacy in protecting therapeutic cells. Safety and clinical data support a wide range of application areas and we are inviting academic and company partners to expose IBsolvMIR to clinical use.
By working closely in partnership with leading academic institutions, CROs, and consultants, we are creating a new opportunity for successful cell therapy with IBsolvMIR.
We are currently seeking partners with well-documented therapies and the ambition to improve patient outcomes in clinical studies.
Contact us for more information on development partnerships.